Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas
Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas
复制标题
DOI：
10.1309/gfcllrh8a68xkmjn
复制
发表时间：
2008-05-01
影响因子：
3.5
通讯作者：
Kim, Hoguen
中科院分区：
文献类型：
--
作者：
Lee, Hanna;Rhee, Hwanseok;Kim, Hoguen
最近的遗传学研究发现了许多在结直肠癌中差异表达的基因。为了验证结直肠癌中上调的基因，我们进行了酶联免疫吸附试验。从40个结直肠癌和35个匹配的正常粘膜样本的基因表达数据中选择候选标记。基于密集过滤，选择9个基因用于进一步评估。其中，筛选巨噬细胞移动抑制因子（MIF）、巨噬细胞介素β A（BM-beta A）、趋化因子配体10（chemokine ligand 10），并将结果与129例结肠癌患者和53例健康对照者血清样本中的癌胚抗原（CEA）进行比较。我们发现大肠癌患者血清MIF水平显著升高。与CEA相比，MIF对早期癌的检出率更高（47.3%比29.5%）。但特异性不及CEA（90.6%vs100.0%）。我们的研究结果表明，MIF可以作为一个诊断标记物在结直肠癌。
Recent genetic studies have identified many differentially expressed genes in colorectal carcinomas. For validation of up-regulated genes in colorectal carcinomas, we performed an enzyme-linked immunosorbent assay. Candidate markers were selected from gene expression data for 40 colorectal cancers and 35 matched normal mucosal samples. Based on intensive filtering, 9 genes were selected for the further evaluations. Among them, macrophage migration inhibitory factor (MIF), inhibin beta A, and chemokine ligand 10 were screened, and the results were compared with carcinoembryonic antigen (CEA) in serum samples of 129 patients with colon cancer and 53 healthy control subjects. We found that the serum MIF level was significantly increased in patients with colorectal cancer. Compared with CEA, MIF was more sensitive in early cancer detection (47.3% vs 29.5%). However, the specificity was not as high as that of CEA (90.6% vs 100.0%). Our findings indicate that MIF may be used as a diagnostic marker in colorectal carcinomas.